Durham, NC, United States of America

Paul L Feldman


Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 78(Granted Patents)


Company Filing History:


Years Active: 1991-2025

Loading Chart...
8 patents (USPTO):

Title: The Innovative Contributions of Paul L. Feldman

Introduction

Paul L. Feldman, an accomplished inventor based in Durham, NC, is renowned for his significant contributions to pharmaceutical innovation. With a portfolio of seven patents, Feldman has made strides in developing compounds that address important health issues.

Latest Patents

Feldman's recent patents encompass groundbreaking discoveries in the field of medicinal chemistry. One notable patent details substituted pyrrolidines—novel compounds that inhibit the functionality of Type IV phosphodiesterase (PDE-IV). These compounds present promising applications for treating inflammatory diseases and conditions related to elevated cytokine levels, in addition to central nervous system (CNS) disorders. Another key patent involves intermediates for creating analgesic N-phenyl-N-(3-OR) and N-phenyl-N-(4-piperidinyl) amides, which demonstrate potent analgesic activity.

Career Highlights

Throughout his career, Paul L. Feldman has worked with esteemed companies such as Glaxo Inc. and Glaxo Wellcome Inc. His work at these organizations has not only propelled his career forward but also contributed significantly to the advancement of medicinal innovations.

Collaborations

Feldman has collaborated with fellow innovators Marcus F. Brackeen and Michael K. James. These cooperative efforts have likely enriched his research and development endeavors, enhancing the overall impact of his innovative works.

Conclusion

In summary, Paul L. Feldman's innovative spirit and dedication to his field are evident in his valuable patents and collaborations. His work continues to pave the way for advancements in medicine, particularly in the treatment of various health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…